However, this study has limitations, including a lack of data for PHLDA2 expression in normal colorectal cells, other protein inhibitors of the PI3K/AKT pathway were not assessed, and the limited number of CRC samples that were evaluated. Here, PHLDA2 is linked to colorectal carcinoma.